Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_459549086df37b5bed0003502de7e7aa |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
filingDate |
2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50f6c50b50ce674e58fa71541f5d50e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a800b301db95038eb23f44fc41443ddf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5d0f4d4924360701638e5a4e7cce436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c86304d49b319d31ceead1ea4bdc82c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be13704bd93a8b278011e76852525f90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c14b1ea905065057ef72e8037207423 |
publicationDate |
2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20150123301-A |
titleOfInvention |
Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
abstract |
Donepezil wherein the composition comprises less than about 20% w / w of donepezil when tested in a paddle dissolution device at 50 rpm in a 37 占 폚 900 ml 6.8 buffer for 3 to 6 hours And an amount of more than 90% w / w of donepezil is released after 12 hours. |
priorityDate |
2013-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |